Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/FDA approves Gilead's once-daily HIV pill Bixlenvo for patients needing simpler treatment options.
GILD
$149.97
+$1.11 +0.75%

FDA approves Gilead's once-daily HIV pill Bixlenvo for patients needing simpler treatment options.

Market News
27 Aug 2026
CNBC
View Source
Bullish
pluang ai news

The FDA has approved Bixlenvo, a once-daily HIV pill from Gilead that combines bictegravir and lenacapavir to simplify treatment for patients with suppressed virus but complex regimens. It targets those who cannot use current single-pill options due to drug resistance or side effects, offering a new, effective alternative. Clinical trials showed Bixlenvo maintains viral suppression with manageable side effects, providing an important option especially for older patients with long treatment histories. Gilead aims to expand HIV treatment choices with this and other lenacapavir-based therapies.

More News (GILD)

VanEck Biotech ETF (BBH) is a Buy with strong growth potential from leading biotech firms.

VanEck Biotech ETF (BBH) is a Buy with strong growth potential from leading biotech firms.

The VanEck Biotech ETF (BBH) is recommended as a Buy due to its focused exposure to top biotech companies like Amgen, Gilead, and Vertex, which are entering a new growth phase. These firms support capital growth through diverse drug pipelines, strong...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App